Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 14/20 | 1.00 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.64 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.61 |
| ▸ | DHODH | Q02127 | 1/20 | 0.58 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7034062 | 0.90 | ACLY (0.82) | ACLYSUCNR1SERPINE1DHODHMAPT | |
| SCHEMBL2274563 | 0.89 | ACLY (0.81) | ACLYSUCNR1SERPINE1DHODHGRIK1 | |
| SCHEMBL2268331 | 0.89 | ACLY (0.80) | ACLYSUCNR1SERPINE1DHODHGRIK1 | |
| SCHEMBL2274998 | 0.89 | ACLY (0.80) | ACLYSUCNR1SERPINE1DHODHGRIK1 | |
| SCHEMBL21930987 | 0.88 | ACLY (1.00) | ACLYSUCNR1SERPINE1 | |
| SCHEMBL2272049 | 0.87 | ACLY (0.78) | ACLYSUCNR1SERPINE1DHODHGRIK1 | |
| SCHEMBL22000117 | 0.87 | ACLY (0.77) | ACLYSUCNR1SERPINE1MAPT | |
| SCHEMBL2270222 | 0.87 | DHODH (0.77) | ACLYSUCNR1SERPINE1DHODHGRIK1 | |
| SCHEMBL2275453 | 0.87 | ACLY (0.76) | ACLYSUCNR1SERPINE1DHODHGRIK1 | |
| SCHEMBL2276482 | 0.85 | ACLY (0.74) | ACLYSUCNR1SERPINE1DHODHGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555012-B2 | ACLY inhibitors and uses thereof | Nimbus Artemis, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| CN-101094829-A | Novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885SUCNR1 836/4885SERPINE1 1846/4885 |
| US-11555012-B2 | ACLY inhibitors and uses thereof | ACLY, ATP5ME, ATP5MG | ACLY 1/4885SUCNR1 836/4885SERPINE1 1846/4885 |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ACLY 653/4885SUCNR1 637/4885SERPINE1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.